Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsAetna medical‑benefit drug list Coverage | OpenPay…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentAetnaPolicy 4230468-01-03 (07/25)

    Aetna Commercial Clinical Program Summary — Medical‑Benefit Drug List and Coverage Guidance

    Customize your policy alerts

    Sign up for Aetna Policy 4230468-01-03 (07/25) alerts

    Get alerted when Policy 4230468-01-03 (07/25) changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Lists medications covered under Aetna's commercial medical benefit with associated therapeutic class, HCPCS codes, precertification requirement, preferred alternatives, and site-of-care indicators; intended for providers submitting or requesting coverage for infused/injected and other medical-benefit drugs.

    Policy Summary
    PayerAetna
    PolicyAetna Commercial Clinical Program Summary — Medical‑Benefit Drug List and Coverage Guidance
    Policy CodePolicy 4230468-01-03 (07/25)
    Change TypeNo material change
    Effective Date
    Next Review Date
    Key ActionObtain precertification/prior authorization per Aetna's Provider Precertification List for drugs marked 'Precert required = Y' before administration and billing.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    100+medications listed (partial)
    Y/N notedprecert flag
    Site of Caresite-of-care flags
    CBMCombined Benefit Mgmt

    Coverage Criteria and Formulary Placement

    General coverage condition

    Covered when administrative requirements are met and precertification (when required) is obtained

    Program-level requirements: Drug is covered under the Aetna commercial medical benefit when listed in this summary and when provider follows Aetna clinical drug policies and obtains required precertification for drugs where 'Precert required = Y'.

    Clinical eligibility and detailed medical necessity criteria are in separate Clinical Policy Bulletins and the Provider Precertification List.

    Formulary placement / benefit assignment

    Coverage and benefit placement as listed

    formulary_entry: Each drug row records therapeutic class, HCPCS/J/Q code, precert required (Y/N), preferred alternative, and site-of-care; some drugs are designated Preferred, Non-Preferred, Excluded, Medical coverage only, or Pharmacy coverage only under the Combined Benefit Management program.

    Administrative coverage placement; no clinical eligibility rules in this fragment

    Policy Summary
    PayerAetna
    PolicyAetna Commercial Clinical Program Summary — Medical‑Benefit Drug List and Coverage Guidance
    Policy CodePolicy 4230468-01-03 (07/25)
    Change TypeNo material change
    Effective Date
    Next Review Date
    Key ActionObtain precertification/prior authorization per Aetna's Provider Precertification List for drugs marked 'Precert required = Y' before administration and billing.
    SourceLink
    On This Page
    Coverage Criteria and Formulary PlacementHCPCS / J / Q CodesPrecertification, Prior Authorization, and Provider RequirementsSite-of-Care DesignationsBiosimilar Preferences and NotesTable and Flag DefinitionsStep Therapy and Preferred AlternativesPolicy Background and ScopeRevision History

    Formulary placement (per-drug)

    Coverage stance is expressed per drug as Preferred, Non-Preferred, Excluded, and as Pharmacy vs Medical benefit where indicated.

    formulary_entries: Each listed drug has an associated benefit channel and formulary status (Preferred, Non-Preferred, Excluded) and where specified indicates Pharmacy vs Medical benefit (e.g., SIMPONI ARIA = Medical coverage only; several MS and colony-stimulating-factor products show mixed pharmacy/medical statuses).

    No nested clinical criteria provided in these chunks.

    This summary is a program-level listing of medical‑benefit medications and administrative attributes. It does not contain the detailed clinical eligibility rules or specific clinical exclusions for any drug. Coverage of a listed medication is contingent on meeting the administrative requirements in this summary and obtaining any required precertification; the specific medical necessity criteria, clinical exclusions, and documentation requirements are contained in the referenced Clinical Policy Bulletins and the Provider Precertification List.

    Some biosimilar entries include a usage note indicating they are not appropriate for certain indications. For example, the biosimilar listing for Mvasi carries an explicit notation that it is "not indicated for ocular conditions" in the table, and Avastin is listed elsewhere as the preferred alternative for ophthalmic injectables. Providers should follow those indication notes when selecting an agent for ocular use and consult the underlying clinical policies for formal coverage guidance.

    The Combined Benefit Management section shows that formulary placement and benefit channel can differ by product and by benefit. For example, INFLECTRA is listed as Excluded under the pharmacy benefit but Preferred under the medical benefit in the extract; similarly, several colony‑stimulating factor biosimilars and branded agents show mixed Excluded/Preferred/Non‑Preferred statuses depending on whether the listing applies to pharmacy or medical coverage. Verify benefit assignment for each product and member when planning therapy.

    Certain products are explicitly marked Excluded in the drug list. Examples in the Combined Benefit Management extract include BRIUMVI and LEMTRADA (MS non‑orals category) and select osteoporosis injectables such as EVENITY and TERIPARATIDE. These exclusion flags indicate the product is not covered under the specified benefit channel shown in the table; check clinical policies and plan documents for any available exceptions or alternative coverage pathways.

    This summary does not enumerate specific circumstances labeled as "not medically necessary." Determinations that a service or drug is not medically necessary are made in the payer's detailed Clinical Policy Bulletins and related clinical policies; providers should consult those documents for clinical NMN criteria and appeal processes.

    The document states that "Not all health services are covered" and directs readers to plan documents for a complete description of benefits, exclusions, limitations, and conditions of coverage. The program summary itself does not include explicit 'not medically necessary' clinical statements; coverage limits and exclusions are defined in the member's plan documents and in the payer's clinical policies.

    HCPCS / J / Q Codes

    Sample listed HCPCS/Q codes (partial list)HCPCS
    Q2055Abecma HCPCS code
    J3262Actemra IV HCPCS code
    J0801Acthar Gel HCPCS code
    Additional HCPCS/Q codes (partial list)HCPCS
    Q5124Byooviz HCPCS code
    J0178Eylea HCPCS code
    J1428Exondys 51 HCPCS code
    Covered HCPCS entries (partial list)HCPCS
    J3490Epysqli (HCPCS J3490)
    J3590Epysqli (HCPCS J3590)
    C9399Epysqli (HCPCS C9399)
    J9055Erbitux
    J7204Esperoct
    J7323Euflexxa
    J3111Evenity
    J1305Evkeeza
    Mixed HCPCS/J codes (partial list)HCPCS
    J3490Myalept; Nulibry; Opuviz; Rivfloza; Strensiq; Skytrofa; many others listed under J3490
    Mixed HCPCS/J codes (alternate unspecified drug code)HCPCS
    J3590Myalept; Nulibry; Opuviz; Omisirge; Pavblu; many others listed under J3590
    Sample explicit HCPCS/Q codes from extractHCPCS
    J0587Myobloc
    J1458Naglazyme
    J2506Neulasta, Neulasta Onpro
    J1442Neupogen
    J0219Nexviazyme
    Q5110Nivestym
    J0725Novarel, Ovidrel, Pregnyl (injectable infertility medications)
    J7182NovoEight
    J7189NovoSeven RT
    J2182Nucala
    Additional HCPCS/Q/S codesHCPCS
    Q5114Ogivri
    J3590Omisirge (also listed under other codes)
    J2267Omvoh
    J0222Onpattro
    Q5112Ontruzant
    J9299Opdivo IV
    J1745Remicade ++
    J1300Soliris
    J1930Somatuline Depot
    J2326Spinraza
    1–10 of 13
    1/2
    RSV prophylaxis codesmixed
    S9562Synagis (RSV prophylaxis)
    90378Synagis (alternative code)
    HCPCS codes captured in this partial listingHCPCS
    J2779Supartz FX
    J9226Supprelin LA
    J2781Syfovre
    S9562Synagis
    90378Synagis (alternate code listed)
    J7331Synojoynt
    J7325Synvisc / Synvisc-One
    J0593Takhzyro
    J3055Talvey
    Q2053Tecartus
    1–10 of 79
    1/8
    Multiple Sclerosis Non-Orals J-codesHCPCS
    J2329BRIUMVI
    J9302KESIMPTA
    J0202LEMTRADA
    J2350OCREVUS
    J3590OCREVUS ZUNOVO
    J2323TYSABRI
    Autoimmune Infused Other J-codesHCPCS
    J1602SIMPONI ARIA
    Hematologic / Colony Stimulating Factors J/Q-codesHCPCS
    Q5108FULPHILA
    Q5130FYLNETRA
    J2506NEULASTA Injectable / NEULASTA ONPRO
    Q5122NYVEPRIA
    J1449ROLVEDON
    Q5127STIMUFEND
    Q5111UDENYCA
    Q5120ZIEXTENZO
    Osteoporosis Injectable J-codesHCPCS
    J3111EVENITY
    J3110FORTEO / TERIPARATIDE
    J0897PROLIA
    J3590TYMLOS
    Applicable states for non-preferred medical status
    Applicable statesAK, AR, GA, LA, MN, MS, ND, OK, RI, TN, TX, VT
    ScopeStates listed apply to non-preferred status on the medical benefit under the Combined Benefit Management Drug List
    Applies toAetna commercial fully insured medical and pharmacy benefit members (subject to state law) — excludes Aetna Health Exchange, Federal, Medicare and Medicaid plans

    Precertification, Prior Authorization, and Provider Requirements

    Prior Authorization

    Precertification, Prior Authorization, and Provider Requirements

    Many provider-administered drugs listed in this document require precertification or prior authorization before administration. Entries with the field "Precert required = Y" (and the associated HCPCS/Q-codes) indicate a required prior authorization or precertification step. Claims may be denied or delayed if required precertification/prior authorization is not obtained.

    • Precertification required for many drugs: Multiple J-, Q-, C-, and S- HCPCS-coded drugs in the list are marked 'Precert required = Y' (e.g., Abecma Q2055; Actemra IV J3262; Adakveo J0791; many others).
    • Prior authorization / benefit management indicated: Drugs listed with 'Precert required = Y' are subject to Aetna's clinical drug policies and benefit management (site-of-care requirements, quantity limits, step/therapeutic substitution guidance).
    • Documentation for precertification: Providers must submit the required prior authorization request through Aetna's precertification process and include clinical documentation supporting medical necessity, HCPCS/temporary codes, diagnosis, dosing, and any trial/step history as applicable.
    • Required documentation and reference guidance: Refer to the Provider Precertification List, Site of Care Policy, and applicable Clinical Policy Bulletins for detailed submission requirements and supporting documentation.
    • Precert indication present: Each drug row includes a 'Precert required = Y/N' indicator and HCPCS/temporary billing codes; use these to determine if prior authorization is required prior to claim submission.
    • Member coverage verification: Verify member-specific benefits, medical versus pharmacy benefit assignment, and copay/coverage details via the member website or by calling the toll-free number on the member ID card.
    • Denial risk from missing precertification or policy compliance: Failure to obtain required precertification/prior authorization or to follow Aetna clinical policies, site-of-care rules, or benefit design may result in claim denial, payment delay, or member financial liability.
    • Preferred-alternative / step guidance: Many entries list a 'Preferred Alternative' (including biosimilars or therapeutic alternatives such as Avastin for ophthalmic injectables, Kanjinti/Trazimera for Herceptin, or Monovisc/Orthovisc/Synvisc One for viscosupplements). When a preferred alternative is listed, coverage preference or step requirements may apply.
    • Preferred alternatives may impose coverage preference: The Combined Benefit Management Drug List shows pharmacy vs medical benefit status and formulary preference (Preferred, Non-Preferred, Excluded) which can affect coverage and require step therapy or substitution to a preferred agent.
    • Formulary preference — no step sequences specified: The document lists formulary preference statuses and benefit assignments but does not specify detailed step-therapy sequences; consult the clinical policy or precertification requirements for step details.
    Documentation Required

    Provider submission and documentation guidance

    Operational notes and actions for providers submitting requests:

    • Include the HCPCS/Q-code(s) exactly as billed and indicate the 'Precert required' flag shown in the drug list when initiating a prior authorization request.
    • Attach supporting clinical records (diagnosis, prior therapies/trials, lab results, and dosing schedule) as required by the applicable Clinical Policy Bulletin.
    • Check Site of Care indicators where present (Site of Care = Y) to determine if administration location or alternate site authorization is required.
    • When a drug is listed on the Combined Benefit Management Drug List, confirm whether the product is covered under the pharmacy benefit, medical benefit, or is excluded for the member's plan.
    • For questions about coverage or to confirm required documentation, contact Aetna or use the provider portal; for member-specific coverage/cost details, direct members to their member website or ID card phone number.
    Step Therapy

    Preferred alternatives and step therapy

    Step-therapy and preferred product guidance — what to watch for:

    • When a preferred alternative is listed, Aetna may require trial/failure of the preferred agent(s) or documentation of medical rationale for use of the non-preferred product.
    • Biosimilar and therapeutic substitution guidance is indicated for many oncology, immunologic, and supportive-care agents (e.g., Zarxio as a preferred alternative to Neupogen; Kanjinti/Trazimera for Herceptin).
    • Formulary preference categories (Preferred, Non-Preferred, Excluded) in the Combined Benefit Management Drug List affect coverage and may require prior authorization or step edits; consult the list for benefit assignment details.
    Denial Risk

    Denial risk from missing precertification or policy noncompliance

    Denial and billing risk if requirements are not met.

    • Claims for HCPCS-coded provider-administered drugs marked 'Precert required = Y' may be denied if authorization is not obtained prior to service.
    • Noncompliance with Aetna clinical drug policies, missing documentation, or failure to follow site-of-care or benefit-management requirements can result in claim denials and member liability.
    • Prior authorization approvals are specific to the clinical information and codes submitted; billing a different code, dose, or indication than approved can lead to payment adjustments or denials.

    Site-of-Care Designations

    Note
    Note
    Note
    Note
    Note

    Biosimilar Preferences and Notes

    Note
    Note
    Note
    Note
    Note
    Note
    Note

    Table and Flag Definitions

    Table column definitions
    Medication NameColumn identifies the drug/product name in the table
    1 = Therapeutic ClassNumeric column '1' lists the drug's therapeutic class
    2 = HCPCS codeNumeric column '2' lists the HCPCS, J- or Q-code when provided
    3 = Precert requiredNumeric column '3' indicates whether precertification/prior authorization is required (Y/N)
    4 = Preferred AlternativeNumeric column '4' lists a preferred alternative agent where applicable
    5 = Site of CareNumeric column '5' indicates site-of-care flag or designation
    Precertification flag (Y/N)
    Precert required flagIndicates whether prior authorization is required; values = Y or N
    Examples (Y)Multiple listed drugs show 'Precert required = Y' (e.g., Epysqli J3490/J3590/C9399; Myalept J3490/J3590)
    UsageProviders must obtain precertification for drugs flagged 'Y' per Aetna's Provider Precertification List
    Site of Care indicator (Y/blank)
    Site of Care indicatorIndicates whether a payer-designated site-of-care designation applies; values = Y or blank
    Examples (Y)Epysqli and Evkeeza are shown with 'Site of Care = Y'; Naglazyme and Nexviazyme also show 'Y' in entries
    Interpretation'Y' denotes the payer has specified a site of administration (e.g., infusion center, hospital outpatient); blank = not specified
    Payer prior authorization / precertification requirement
    Precert required (payer)Denotes whether prior authorization is required by the payer for the listed drug; values = Y or N
    Documented usageMany HCPCS-coded products in the list are marked 'Precert required = Y' indicating prior authorization is required for coverage
    Provider actionSubmit prior authorization per Aetna process using the listed HCPCS/J/Q/C codes when 'Y' is indicated
    Combined Benefit Management
    Combined Benefit ManagementDrugs listed under the Combined Benefit Management Drug List are managed for benefit channel and coverage status
    Program noteSome drugs under this program may only be available on the member's prescription or medical benefit; applies to Aetna commercial fully insured plans (subject to state law)
    ReferenceSee Combined Benefit Management Drug List section for benefit-specific statuses (Preferred, Non-Preferred, Excluded, Pharmacy/Medical only)
    Formulary status labels
    PreferredDrug has the highest coverage level under the benefit category
    Non-PreferredDrug may cost the member more out of pocket under the benefit category
    ExcludedDrug is not covered under the benefit category
    HCPCS billing codes for infused/injectable agents
    J-code / Q-codeHCPCS billing codes (J- and Q-codes) are provided for infused or injectable agents in the table
    ExamplesExamples in the list include J2506 (Neulasta), J2323 (Tysabri), Q5111 (Udenyca), Q5108 (Fulphila)
    UsageCodes are intended for billing and for supporting precertification/prior authorization requests

    Step Therapy and Preferred Alternatives

    Drug / CategoryPreferred Alternative(s)
    Euflexxa (Viscosupplements)
    Monovisc; Orthovisc; Synvisc One
    Hyalgan (Viscosupplements)
    Monovisc; Orthovisc; Synvisc One
    Herceptin (Oncology)
    Kanjinti; Trazimera
    Infliximab (Immunologic Agents)
    Avsola; Inflectra; Renflexis
    Eylea / Cimerli (Ophthalmic injectables)
    Avastin; Byooviz; Cimerli
    Drug / CategoryPreferred Alternative(s)
    Supartz FX (Viscosupplements)
    Monovisc; Orthovisc; Synvisc One
    Synvisc / Synvisc-One (Viscosupplements)
    Monovisc; Orthovisc; Synvisc One
    Eylea (Ophthalmic medical injectables)
    Avastin; Byooviz; Cimerli
    Izervay (Ophthalmic medical injectables)
    Syfovre
    Drug / CategoryPreferred Alternative(s)
    Nypozi (G-CSF)
    Zarxio
    Nyvepria (G-CSF)
    Fulphila; Neulasta; Neulasta Onpro
    Retacrit (Darbepoetin/Epoetin)
    Aranesp; Procrit
    Drug / CategoryFormulary Status (Pharmacy / Medical)
    AVSOLA (Autoimmune - Infliximab)
    Preferred / Preferred
    INFLECTRA (Autoimmune - Infliximab)
    Excluded / Preferred
    REMICADE (Autoimmune - Infliximab)
    Preferred / Pharmacy coverage only
    BRIUMVI (Multiple Sclerosis Non-Orals)
    Excluded / Non-Preferred
    KESIMPTA (Multiple Sclerosis Non-Orals)
    Preferred / Pharmacy coverage only
    SIMPONI ARIA (Autoimmune Infused Other)
    Medical coverage only / Preferred
    FULPHILA (Colony Stimulating Factors)
    Preferred / Non-Preferred
    NEULASTA (Colony Stimulating Factors)
    Excluded (Pharmacy) / Non-Preferred (Medical)
    EVENITY (Osteoporosis Injectable)
    Excluded (Pharmacy coverage only)
    NoteImplication
    Formulary statuses are listed as Preferred, Non-Preferred, or Excluded across pharmacy and medical benefit channels.
    These listings indicate relative coverage preference but the document does not define step therapy sequences.
    Some drugs are designated 'Pharmacy coverage only' or 'Medical coverage only' (e.g., SIMPONI ARIA = Medical coverage only).
    Benefit-specific preferences may differ by drug (e.g., INFLECTRA Excluded on pharmacy but Preferred on medical).

    Policy Background and Scope

    This is a program‑level formulary summary that maps a large set of medical‑benefit medications to their therapeutic classes, HCPCS/J/Q billing codes, precertification requirement (Y/N), listed preferred alternatives, and site‑of‑care flags. It supplements but does not replace detailed clinical drug policies: providers must follow the Provider Precertification List, Site of Care Policy, and Clinical Policy Bulletins for documentation, prior authorization, and medical necessity determinations.

    Revision History

    July 2025formulary_updateLatest

    Combined Benefit Management listing for infliximab biosimilars updated: Avsola (Q5121) listed as Preferred for both benefits; Inflectra (Q5103) listed as Excluded on pharmacy but Preferred on medical; Infliximab/Remicade (J1745) listed as Preferred with pharmacy coverage only; Renflexis (Q5104) listed as Excluded on pharmacy but Preferred on medical.